Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status

BJU International

Volumn 96, Issue 1, 2005, Pages 117-126

  Thamilselvan, Sivagnanam ^a   Menon, Mani ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Antioxidants; Ethylene glycol; Hyperoxaluria; Lipid peroxidation; Sprague Dawley rats; Urolithiasis; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; CALCIUM OXALATE; ENZYME; ETHYLENE GLYCOL; FREE RADICAL; GLUTATHIONE; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM OXALATE STONE; CALCIUM URINE LEVEL; CELL DAMAGE; CONTROLLED STUDY; DIET; ENZYME ACTIVITY; ENZYMURIA; FLUID INTAKE; HISTOPATHOLOGY; HYPEROXALURIA; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RAT STRAIN; URINE PH; URINE VOLUME; UROLITHIASIS; VITAMIN INTAKE;

ANIMALS; ANTIOXIDANTS; CALCIUM OXALATE; CRYSTALLIZATION; HYPEROXALURIA; KIDNEY CALCULI; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; VITAMIN E;

EID: 21744445645     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05579.x     Document Type: Article

References (60)

1. Robertson WG, Peacock M. Pathogenesis of urolithiasis. In Schneider HJ ed. HS-V & Urolithiasis, Etiology, Diagnosis. Chapter 3. New York, Springer 1985:185-301
2. Hodgkinson A. Oxalic add in Biology and Medicine. New York: Academic Press 1984
3. Robertson WG. Urinary Tract Calculi. In Nordin BEC, AG Na HAM, Hong Kong: Churchill Livingston, 1993: 249
4. Laker MF. The clinical chemistry of oxalate metabolism. Adv Clin Chem 1983; 23: 259-97
5. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59: 270-6
6. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med 1989; 111: 1006-9
7. Menon M, Koul H. Clinical review 32: Calcium oxalate nephrolithiasis. J Clin Endocrinol Metab 1992; 74: 703-7
8. Smith LH. Idiopathic calcium oxalate urolithiasis. Endocrinol Metab Clin North Am 1990; 19: 937-47
9. Tiselius HG. Possibilities for preventing recurrent calcium stone formation. Principles for the metabolic evaluation of patients with calcium stone disease. BJU Int 2001; 88: 158-68
10. Thamilselvan S, Khan SR, Menon M. Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 2003; 31: 3-9
11. Thamilselvan S, Byer KJ, Hackett RL, Khan SR. Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 2000; 164: 224-9
12. Thamilselvan S, Selvam R. Effect of vitamin E and mannitol on renal calcium oxalate retention in experimental nephrolithiasis. Indian J Biochem Biophys 1997; 34: 319-23
13. Thamilselvan S, Khan SR. Oxalate and calcium oxalate crystals are injurious to renal epithelial cells: results of in vivo and in vitro studies. J Nephrol 1998; 11 (Suppl. 1): 66-9
14. Bhandari A, Koul S, Sekhon A et al. Effects of oxalate on HK-2 cells, a line of proximal tubular epithelial cells from normal human kidney. J Urol 2002; 168: 253-9
15. Scheid C, Koul H, Hill WA et al. Oxalate toxicity in LLC-PK1 cells, role of free radicals. Kidney Int 1996; 49: 413-9
16. Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol 1978; 52: 302-10
17. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Meth Enzymol 1994; 233: 346-57
18. Arnaud J, Fortis I, Blachier S, Kia D, Favier A. Simultaneous determination of retinol, alpha-tocopherol and beta-carotene in serum by isocratic high-performance liquid chromatography. J Chromatogr 1991; 572: 103-16
19. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-5
20. Sinha AK. Colorimetric assay of catalase. Anal Biochem 1972; 47: 389-94
21. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-22
22. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Laboratory Clin Med 1967; 70: 158-69
23. Goldberg DM, Spooner RJ. Glutathione reductase. In Berameyer HV ed. Methods of Enzymatic Analysis. 3rd edn. New York: Academic Press, 1983: 258-65
24. Deutsch J. Glucose-6-phosphate dehydrogenase. In Bergmeyer HV ed. Methods in Enzymatic Analysis. 3rd edn. Vol. 3. New York: Academic Press, 1983: 190-7
25. Crocker CL. Rapid determination of urea nitrogen in serum or plasma without deproteinization. Am J Med Technol 1967; 33: 361-5
26. Hare RS. Endogenous creatinine in serum and urine. Proc Soc Exp Biol Medical 1950; 74: 148-51
27. Thamilselvan S, Hackett RL, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 1997; 157: 1059-63
28. Vassault A. Lactate dehydrogenase. In Bergmeyer HV ed. Methods in Enzymatic Analysis. 3rd edn. Vol. 3. New York: Academic Press, 1983: 118-26
29. Jung K, Scholz D. An optimized assay of alanine aminopeptidase activity in urine. Clin Chem 1980; 26: 1251-4
30. Khan SR, Hackett RL. Calcium oxalate urolithiasis in the rat. is it a model for human stone disease? A review of recent literature. Scon Electron Microsc 1985; PT2: 759-74
31. Kumar S, Sigmon D, Miller T et al. A new model of nephrolithiasis involving tubular dysfunction/injury. J Urol 1991; 146: 384-9
32. de Bruijn WC, Boeve ER, van Run PR et al. Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 1995; 9: 103-14
33. de Bruijn WC, Boeve ER, van Run PR et al. Etiology of calcium oxalate nephrolithiasis in rats. II. The role of the papilla in stone formation. Scanning Microsc 1995; 9: 115-25
34. Khan SR. Animal models of kidney stone formation: an analysis. World Urol 1997; 15: 236-43
35. Palozza P, Krinsky NI. The inhibition of radical-initiated peroxidation of microsomal lipids by both alpha-tocopherol and beta-carotene. Free Radic Biol Med 1991; 11: 407-14
36. Kadiiska MB, Hanna PM, Jordan SJ, Mason RP. Electron spin resonance evidence for free radical generation in copper-treated vitamin E- and selenium-deficient rats: in vivo spin-trapping investigation. Mol Pharmacol 1993; 44: 222-7
37. Grases F, Garcia-Ferragut L, Costa-Bauza A. Development of calcium oxalate crystals on urothelium: effect of free radicals. Nephron 1998; 78: 296-301
38. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 2003; 62: 1123-8
39. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005; 33: 65-9
40. Polidori MC, Mecocci P, Stahl W, Sies H. Cigarette smoking cessation increases plasma levels of several antioxidant micronutrients and improves resistance towards oxidative challenge. Br J Nutr 2003; 90: 147-50
41. Guerri C, Montoliu C, Renau-Piqueras J. Involvement of free radical mechanism in the toxic effects of alcohol: implications for fetal alcohol syndrome. Adv Exp Med Biol 1994; 366: 291-305
42. Khan SR, Shevock PN, Hackett RL Urinary enzymes and calcium oxalate urolithiasis. J Urol 1989; 142: 846-9
43. Baggio B, Gambaro G, Ossi E, Favaro S, Borsatti A. Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol 1983; 129: 1161-2
44. Jordan WR, Finlayson B, Luxenberg M. Kinetics of early time calcium oxalate nephrolithiasis. Invest Urol 1978; 15: 465-8
45. Larsson L, Tiselius HG. Hyperoxaluria. Miner Electrolyte Metab 1987; 13: 242-50
46. Weinman EJ, Frankfurt SJ, Ince A, Sansom S. Renal tubular transport of organic acids. Studies with oxalate and para-aminohippurate in the rat. J Clin Invest 1978; 61: 801-6
47. Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 1978; 15: 442-8
48. Wiessner JH, Hung LY, Mandel NS. Crystal attachment to injured renal collecting duct cells, influence of urine proteins and pH. Kidney Int 2003; 63: 1313-20
49. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol 1997; 272: F55-62
50. Cao LC, Jonassen J, Honeyman TW, Scheid C. Oxalate-induced redistribution of phosphatidylserine in renal epithelial cells: implications for kidney stone disease. Am J Nephrol 2001; 21: 69-77
51. Khan SR, Byer KJ, Thamilselvan S et al. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol 1999; 10 (Suppl. 14): 5457-63
52. Hackett RL, Shevock PN, Khan SR. Cell injury associated calcium oxalate crystalluria. J Urol 1990; 144: 1535-8
53. Smith CL. Calcium oxalate crystal adherence in the rat bladder, restoration of anti-adherence after acid treatment. J Urol 2004; 171: 882-4
54. Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS. Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 2001; 59: 637-44
55. Shvedova AA, Tyurina JY, Kawai K et al. Selective peroxidation and externalization of phosphatidylserine in normal human epidermal keratinocytes during oxidative stress induced by cumene hydroperoxide. J Invest Dermatol 2002; 118: 1008-18
56. Meydani M. Vitamin E. Lancet 1995; 345: 170-5
57. Swanson JE, Ben RN, Burton GW, Parker RS. Urinary excretion of 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxylchroman is a major route of elimination of gamma-tocopherol in humans. J Lipid Res 1999; 40: 665-71
58. Schultz M, Leist M, Petzika M, Gassmann B, Bridglius-Flohe R. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2 (2′-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? Am J Clin Nutr 1995; 62: 1527S-34S
59. Betancor-Fernandez A, Sies H, Stahl W, Poridori MC. In vitro antioxidant activity of 2,5,7,8-tetramethyl-2-(2′-carboxyethyl-6-hydroxylchroman (alpha-CEHC), a vitamin E metabolite. Free Rad Res 2002 36: 915-21
60. Appenroth D, Karge E, Kiebling G, Wechter WJ, Winnefeld K, Fleck C. LLU-alpha, an endogenous metabolite of gamma-tocopherol, is more effective against metal nephrotoxicity in rats than gamma-tocopherol. Toxicol Lett 2001; 122: 255-65